bendamustine hydrochloride has been researched along with Diffuse Parenchymal Lung Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abi Hatem, N; Dameron, M; Gupta, N; Horowitz, M | 1 |
| Ando, K; Kasai, M; Matsumoto, Y; Ogawa, Y; Ogura, M; Ohmachi, K; Shimizu, D; Taniwaki, M; Tobinai, K; Uchida, T; Watanabe, T; Yokoyama, H | 1 |
1 trial(s) available for bendamustine hydrochloride and Diffuse Parenchymal Lung Disease
| Article | Year |
|---|---|
Phase I and pharmacokinetic study of bendamustine hydrochloride in relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Bendamustine Hydrochloride; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Leukopenia; Lung Diseases, Interstitial; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Male; Metabolic Clearance Rate; Middle Aged; Molecular Structure; Neutropenia; Nitrogen Mustard Compounds; Recurrence; Treatment Outcome | 2010 |
1 other study(ies) available for bendamustine hydrochloride and Diffuse Parenchymal Lung Disease
| Article | Year |
|---|---|
When to consider Pneumocystis jirovecii prophylaxis in HIV-negative patients.
Topics: Aged; Anti-Bacterial Agents; Bendamustine Hydrochloride; HIV Seronegativity; Humans; Immunocompromised Host; Lung Diseases, Interstitial; Lymphoma, Mantle-Cell; Male; Opportunistic Infections; Pneumonia, Pneumocystis; Prednisone; Pulmonary Disease, Chronic Obstructive; Pulmonary Fibrosis; Rituximab; Trimethoprim, Sulfamethoxazole Drug Combination | 2021 |